IceCure Lands Financing following this Morning's Breast Cancer Treatment Adoption Announcement
DENVER, Colo. (247marketnews.com) – IceCure Medical (NASDAQ:ICCM) captured investor attention after reporting, this morning, strong commercial momentum following FDA marketing authorization of its ProSense breast cancer cryoablation platform, as the company announced a 70% increase in its active U.S. commercial install base since receiving FDA clearance in October 2025.
IceCure has since announced a $5.5 million private placement led by a single healthcare-focused institutional investor, providing fresh capital.
The financing was priced at $3.00 per share and includes the purchase of 1.83 million ordinary shares, along with Series D and Series E warrants that could provide additional capital should they eventually be exercised. Gross proceeds are expected to total approximately $5.5 million before fees and expenses, with management indicating that the funds will support working capital needs and broader corporate initiatives as commercialization efforts continue to expand.
Importantly, the financing arrives during a period of increasing visibility for IceCure's ProSense system, which became the first and only cryoablation device to receive FDA marketing authorization for the treatment of low-risk breast cancer in women aged 70 and older when surgery may not be appropriate. The authorization represented a major milestone for the company and opened the door to broader physician adoption across the United States.
Sources